Myelodysplastic Syndrome: From Diagnosis to Treatment

Emma E. Steffensen (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED038000

Clear

$230.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

In this compilation, the authors review the biological aspects of myelodysplastic syndrome disease, diagnosis, and treatment, as well as innovations involving genetics and new treatment perspectives.
Myelodysplastic syndromes are a heterogeneous group of clonal haematopoietic stem cells disorders characterized by dysplasia, as well as peripheral blood cytopenias with a hypercellular marrow and ineffective hematopoiesis.
Myelodysplastic syndromes are frequently associated with acute and chronic inflammation, and autoimmune disorders such as: rheumatoid arthritis, bowel disease, diverse types of vasculitis, autoimmune anemias, several rheumatic and skin disorders, and certain thyroid disorders.
Spliceosome mutations are the most frequent mutations found in blood and bone marrow cells of myelodysplastic syndromes patients. As such, the authors explore the four predominant splicing factor genes: SF3B1, SFRS2, U2AF1, ZRSR2.
Subsequently, this collection discusses the CSNK1A1 gene in the context of myelodysplastic syndromes. It is located at 5q32 within the deleted region, which encodes for casein kinase 1α (CK1α). CK1α is a component of a multiprotein β-catenin destruction complex that regulates Wnt/β-catenin and p53 pathways.
The concluding study focuses on the mutations in epigenetic modifiers occur which myelodysplastic syndromes and drive this disease, such as: DNA methylation, histone acetylation, and RNA interference that alters gene expression.
(Imprint: Nova Medicine and Health)

Preface

Chapter 1. Myelodysplastic Syndrome: An Overview
(Lucas Delmonico, Maria Christina Paixão Maioli and Maria Helena Faria Ornellas, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, and others)

Chapter 2. An Updated Approach to Myelodysplastic Syndromes (MDS)
(Ana Bela Sarmento Ribeiro, Bárbara Marques, Carolina Afonso, Ana Cristina Gonçalves, Nuno Silva, Margarida Coucelo, Paula Laranjeira, Artur Paiva and Emília Cortesão, Laboratory of Oncobiology and Hematology and University Clinic of Hematology/Faculty of Medicine of University of CoimbraS, Coimbra, Portugal, and others)

Chapter 3. The Inflammatory and Autoimmune Dysregulation in Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Chapter 4. Spliceosome Mutations and Alternative Splicing of Pre-Messenger RNA in Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Chapter 5. Myelodysplastic Syndrome with Chromosome 5q: Deletion and Its Treatment
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Chapter 6. Epigenetic Mechanisms and Therapy of Myelodysplastic Syndromes
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Nové Město, Prague, Czech Republic)

Index

You have not viewed any product yet.


SHOW ALL OF MY RECENTLY VIEWED BOOKS